Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Jim Kling

    News

    Novel acetaminophen hepatotoxicity strategy curbs inflammation

    Author:
    Jim Kling
    Publish date: November 12, 2018

    SAN FRANCISCO – A synthetic heparan sulfate molecule may be working in mice by interfering with neutrophil recruitment.

    • Read More

    News

    OV-101 shows promise for Angelman syndrome

    Author:
    Jim Kling
    Publish date: November 6, 2018

    A novel drug affecting the GABAergic system improved sleep problems in a sample of adults and adolescents with Angelman Syndrome.

    • Read More

    News

    Mindfulness training for parents boosted mental health measures

    Author:
    Jim Kling
    Publish date: November 5, 2018

    A small open-label study suggests mindfulness could be a good fit for low-income parents.

    • Read More

    News

    Movement disorders in children warrant screening evaluations

    Author:
    Jim Kling
    Publish date: November 5, 2018

    SEATTLE – Psychiatrists should be able to tackle basic assessment of movement disorders since these can arise for psychopharmacological treatment...

    • Read More

    News

    Three-drug combo proves effective against multidrug-resistant UTIs

    Author:
    Jim Kling
    Publish date: October 29, 2018

    SAN FRANCISCO – A drug combo including EDTA proved superior to meropenem in the treatment of complicated urinary tract infections.

    • Read More

    News

    Talk to adolescents about sexual assault

    Author:
    Jim Kling
    Publish date: October 28, 2018

    SEATTLE – Social worker with expertise in trauma encourages clinicians to ask patients about sexual assault.

    • Read More

    News

    Collaborative approach for suicidal youth helps providers, too

    Author:
    Jim Kling
    Publish date: October 26, 2018

    SEATTLE – The CAMS framework is proven to be effective in adults and is starting to make inroads in the pediatric population.

    • Read More

    Article

    Cholera, bacteriophage in an epic evolutionary struggle

    Author:
    Jim Kling
    Publish date: October 25, 2018

    SAN FRANCISCO – Genetic analyses from samples in a Bangladesh hospital show how Vibrio cholerae and a...

    • Read More

    News

    TB vaccine shows promise in previously infected

    Author:
    Jim Kling
    Publish date: October 18, 2018

    SAN FRANCISCO – A phase 2b trial shows efficacy in individuals previously exposed to TB, but only in those under 25 years.

    • Read More

    News

    Flu vaccination lags among patients with psoriasis

    Author:
    Jim Kling
    Publish date: October 18, 2018

    Dermatologists could play a key role in encouraging flu vaccines in this vulnerable population.

    • Read More

    News

    Stepdown to oral ciprofloxacin looks safe in gram-negative bloodstream infections

    Author:
    Jim Kling
    Publish date: October 15, 2018

    SAN FRANCISCO – A comparison of patients with gram-negative bloodstream infections showed low 90-day treatment...

    • Read More

    Video

    Adjuvanted flu vaccine reduces hospitalizations in oldest old

    Author:
    Jim Kling
    Publish date: October 10, 2018

    SAN FRANCISCO – An adjuvanted trivalent flu vaccine cuts the risk of hospitalizations in nursing home residents by about 6%.

    • Read More

    Video

    Vancomycin loading boost yields better C. diff outcomes

    Author:
    Jim Kling
    Publish date: October 9, 2018

    A heightened loading dose of vancomycin may lead to faster recovery and greater efficacy in Clostridium...

    • Read More

    News

    Oral flu vaccine protects, evokes mucosal immunity

    Author:
    Jim Kling
    Publish date: October 7, 2018

    SAN FRANCISCO – Vaxart’s oral flu vaccine yielded comparable illness rates with an injected quadrivalent...

    • Read More

    News

    Omadacycline equivalent to linezolid for skin infections

    Author:
    Jim Kling
    Publish date: October 7, 2018

    SAN FRANCISCO – The mean reduction in lesion area at the end of treatment was 93.9% for omadacycline and 93.7% for linezolid.

    • Read More

    Pages

    • « first
    • …
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    • 44
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery